Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

Launched by SEOUL NATIONAL HOSPITAL · Apr 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment using special stem cells from a patient’s own blood to help the heart heal after a heart attack, also known as an acute myocardial infarction. The goal is to see if this treatment can improve heart function and safety for patients who have recently experienced a heart attack. The trial is currently looking for participants aged between 19 and 80 who have had a heart attack within the last four weeks and have successfully undergone a procedure to open blocked arteries.

If you or a loved one are considering participating, you would need to meet certain health criteria, such as having a recent heart attack and being in stable condition after treatment. Participants will receive detailed information about the treatment and will need to provide consent to join the trial. It’s important to note that individuals with serious heart failure, active cancers, or other significant health issues may not be eligible. This study aims to find out whether this innovative approach can lead to better recovery outcomes for heart attack patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female aged ≥19 years and ≤ 80 years
• • 2. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization
• • 3. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a drug-eluting stent and/or drug-eluting balloon
• • 4. Agreement to give written informed consent.
• Exclusion Criteria:
• • 1. Patients with uncontrolled heart failure (Killip class ≥ grade 2, or left ventricular ejection fraction \<20%)
• • 2. Patients with uncontrolled chest pain due to ischemia
• • 3. Patients with uncontrolled arrythmia
• • 4. Active malignancy, or incompletely treated malignancy
• • 5. Active infectious disease
• • 6. Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis
• • 7. Presence of non-cardiac comorbidity with life expectancy ≤1 year from randomization
• • 8. Females with childbearing potential or breast-feeding
• • 9. Refusal to give written informed consent
• • 10. Other conditions that may result in protocol non-compliance by the committees